-
-
Humanized model of the immune system
-
iHuPBMC-T
-
iHuPBMC-NK
-
iHuPBMC-B
-
PBMC-LT
-
CD34+ HSC
-
Winn model
-
iHuPBMC-MHC/KO
-
iHuPBMC-OncVax
-
PBMC mixed inoculation model
more -
-
In vivo tumor experimental platform
-
CDX
-
iHuPDX
-
Non-GLP Toxicology
-
PK/PD
-
Brain in situ model
-
Other in situ models
-
Hematologic tumor model system inoculation
-
Creation of high interstitial tumor models
more -
-
In vitro killing experiment platform
-
Immune co-culture killing model
-
CDC
-
In vitro killing experiment platform
-
IC50
-
PDC High-Throughput In Vitro Pharmacodynamics
-
3D organoids
-
ADCC
-
T cell-mediated killing experiment
more -
-
Mouse-derived immune system model
more -
Tumor vaccine
more -
Cell therapy
more -
In vitro testing platform
more -
Non-GLP Toxicology Platform
more -
Non-tumor model and drug efficacy evaluation platform
-
Systematic Vaccination Model
-
Non-tumor model and drug efficacy evaluation platform
-
Skin injury model
-
Stroke model
-
Liver fibrosis model
-
Diabetes model
-
Gouty Arthritis (GA) Model
-
Pulmonary fibrosis model
-
Systemic lupus erythematosus (SLE) model
-
Inflammatory Bowel Disease (IBD) model
-
Rheumatoid Arthritis (RA) Model
more -
-
-
-
PDX model
-
PDX model
-
Head and neck cancer
-
Eye cancer
-
Lung cancer
-
Human breast cancer
-
Esophageal cancer in humans
-
Human gastric cancer
-
Colorectal cancer
-
Human liver cancer
-
Bile duct cancer
-
Gallbladder cancer
-
Human pancreatic cancer
-
Human kidney cancer
-
Human Bladder Cancer
-
Ureteral cancer
-
Prostate cancer
-
Uterine cancer
-
Cervical cancer in women
-
Human Ovarian Cancer
-
Human skin cancer
-
sarcoma
-
Human Nervous System Cancer
-
Embryonal carcinoma
-
Human Lymphoma
-
Human leukemia
-
Multiple Myeloma
-
Adrenal gland
-
Mesothelioma
-
Other people
more -
-
CDX model
-
CDX model
-
Head and neck cancer
-
Eye cancer
-
Lung cancer
-
Human breast cancer
-
Esophageal cancer in humans
-
Human gastric cancer
-
Colorectal cancer
-
Human liver cancer
-
Bile duct cancer
-
Gallbladder cancer
-
Human pancreatic cancer
-
Human kidney cancer
-
Human Bladder Cancer
-
Ureteral cancer
-
Prostate cancer
-
Uterine cancer
-
Cervical cancer in women
-
Human Ovarian Cancer
-
Human skin cancer
-
sarcoma
-
Human Nervous System Cancer
-
Embryonal carcinoma
-
Human Lymphoma
-
Human leukemia
-
Multiple Myeloma
-
Adrenal gland
-
Mesothelioma
-
Other people
more -
-
Homogeneous Model
-
Homogeneous Model
-
Head and neck cancer
-
Eye cancer
-
Lung cancer
-
Breast cancer
-
Stomach cancer
-
Liver cancer
-
Bile duct cancer
-
Gallbladder cancer
-
Pancreatic cancer
-
Kidney cancer
-
Bladder cancer
-
Ureteral cancer
-
Prostate cancer
-
Uterine cancer
-
Cervical cancer
-
Ovarian cancer
-
Esophageal cancer
-
Skin cancer
-
sarcoma
-
Nervous System Cancer
-
Embryonal carcinoma
-
Lymphoma
-
Leukemia
-
Multiple Myeloma
-
Adrenal gland
-
Mesothelioma
-
Other
-
Colorectal cancer
more -
-
News Center
——
InnoModels Biotechnology: Features of the preclinical evaluation platform for tumor vaccines
Author:
InnoModels
Release time:
2024-04-11
With the continuous advancement of cancer treatment, tumor vaccines, as an emerging means of immunotherapy, have received widespread attention. However, the development and evaluation of tumor vaccines require highly specialized platforms to ensure the accuracy and reliability of their experimental data. The InnoModels Biotechnology tumor vaccine preclinical evaluation platform was born to meet this need, and it provides powerful support and tools for tumor vaccine development with its unique features.
1、Comprehensive construction of the immune system
The preclinical evaluation platform for tumor vaccines of InnoModels Biotechnology comprehensively constructs lymphocytes and myeloid cells to ensure the effective presentation of antigens in the body. This comprehensive construction of the immune system enables the platform to more realistically simulate the immune response in the human body, providing more accurate and reliable experimental data for the evaluation of tumor vaccines.
2. Realistic and effective evaluation environment
The platform provides a real and effective evaluation environment for tumor vaccines by highly simulating the response of the human immune system. In this environment, researchers can comprehensively evaluate the effect of tumor vaccines in vivo, including their induced immune response, killing effect on tumor cells, etc., thus providing an important basis for the clinical application of tumor vaccines.

3. Highly customizable experimental design
InnoModels' tumor vaccine preclinical evaluation platform supports highly customizable experimental design to meet the specific needs of different research teams for tumor vaccine evaluation. Researchers can flexibly adjust the experimental conditions, cell types and vaccination methods according to their own research objectives and protocols to obtain more accurate and personalized experimental results.
4、Advanced experimental technology and equipment
The platform adopts advanced experimental technology and equipment to ensure the accuracy and reliability of the experimental process. For example, the platform adopts flow cytometry, real-time fluorescence quantitative PCR and other advanced technologies to accurately detect and quantitatively analyze tumor cells, immune cells and so on. These advanced equipments and technologies provide powerful technical support for researchers, making the experimental results more accurate and credible.
5、Professional technical support and service
InnoModels Biotechnology-Tumor Vaccine Preclinical Evaluation Platform provides professional technical support and services to provide researchers with all-round experimental guidance and assistance. Whether it is experimental design, experimental operation or data analysis, the platform can provide professional guidance and support to ensure that researchers can successfully complete the experiments and obtain accurate experimental results.
In conclusion, with its comprehensively constructed immune system, real and effective evaluation environment, highly customizable experimental design, advanced experimental technology and equipment, as well as professional technical support and services, InnoModels' tumor vaccine preclinical evaluation platform provides powerful support and tools for tumor vaccine R&D and evaluation. It is believed that with the help of the preclinical evaluation platform of tumor vaccines of InnoModels Biotechnology, the research and development and application of tumor vaccines will make greater breakthroughs and progress.
InnoModels Biotechnology (Beijing) Co., Ltd.
-
TEL: +86 15711355061
-
E-mail: xuyl@imodels.tech
-
Address: Building 14, No. 79 West Shuangying Road, Changping District, Beijing
COOKIES
Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy
COOKIES
Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy
These cookies are necessary for basic functions such as payment. Standard cookies cannot be turned off and do not store any of your information.
These cookies collect information, such as how many people are using our site or which pages are popular, to help us improve the customer experience. Turning these cookies off will mean we can't collect information to improve your experience.
These cookies enable the website to provide enhanced functionality and personalization. They may be set by us or by third-party providers whose services we have added to our pages. If you do not allow these cookies, some or all of these services may not function properly.
These cookies help us understand what you are interested in so that we can show you relevant advertising on other websites. Turning these cookies off will mean we are unable to show you any personalized advertising.
InnoModels Biotechnology (Beijing) Co., Ltd